
SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY

1.1 Product identifiers

Product Name : Tofacitinib citrate
Product Number : AUR11052
Manufacturer : Aurora Medbiochem
Address : 938 South Andreasen Drive, Suite E
Escondido, CA 92029 USA

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Manufacture of substances

1.3 Emergency telephone

Emergency Phone # : +1-760-738-1508
Fax Phone # : +1-760-738-1530

SECTION 2: COMPOSITION/INFORMATION ON INGREDIENTS

Components	CAS Number	EC-No.	Molecular Weight	Chemical Formula
Tofacitinib citrate	540737-29-9	--	504.49	C ₁₆ H ₂₀ N ₆ O.C ₆ H ₈ O ₇

SECTION 3: HAZARDS IDENTIFICATION

Product/ Chemical Name	Description	Safety Information
Tofacitinib citrate	White to off-white solid	See below

Emergency Overview:**Classification of the substance or mixture**

Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008.

OSHA Hazards: No known OSHA hazards

GHS Classification: Not a dangerous substance according to GHS

GHS Label elements, including precautionary statements

Pictogram: none

Signal word: none

Hazard statement(s): none

Precautionary statement(s): none

HMIS Classification Health

Hazard: 0

Flammability: 0

Physical hazards: 0

NFPA Rating Health

Hazard: 0

Fire: 0

Reactivity Hazard: 0

Potential Health Effects

Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.

Skin: May be harmful if absorbed through skin. May cause skin irritation.

Eyes: May cause eye irritation.

Ingestion: May be harmful if swallowed.

SECTION 4: FIRST AID MEASURES

General advice

Show this material safety data sheet to the doctor in attendance.

If inhaled: If breathed in, move person into fresh air. If not breathing, give artificial respiration.

In case of skin contact: Wash off with soap and plenty of water.

In case of eye contact: Flush eyes with water as a precaution.

If swallowed: Never give anything by mouth to an unconscious person. Rinse mouth with water.

SECTION 5: FIREFIGHTING MEASURE

Condition of flammability: Not flammable or combustible.

Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Special protective equipment for fire fighters: Wear self-contained breathing apparatus for firefighting if necessary.

Hazardous combustion products: Hazardous decomposition products formed under fire conditions— see section 10

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions: Advice for non-emergency personnel: Do not breathe vapors, aerosols. Avoid substance contact. Ensure adequate ventilation. Keep away from heat and sources of ignition.

Evacuate the danger area, observe emergency procedures, consult an expert.

Environmental precautions: Do not let product enter drains.

Methods for cleaning up: Sweep up and shovel. Keep in suitable, closed containers for disposal

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Advice on safe handling

Work under hood. Do not inhale substance/mixture. Avoid generation of vapours/aerosols.

Advice on protection against fire and explosion

Keep away from open flames, hot surfaces, and sources of ignition. precautionary measures against static discharge.

7.2 Conditions for safe storage, including any incompatibilities

Storage conditions

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature: -20°C. protect from air and light.

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment

Respiratory protection:

Respiratory protection is not required. Where protection from nuisance levels of dusts is desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection:

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of

contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Eye protection:

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166 (EU).

Skin and body protection:

Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific workplace. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Hygiene measures: General industrial hygiene practice.

Control of environmental exposure

Do not let product enter drains.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

Property	Tofacitinib citrate
Appearance:	White to off-white solid
pH:	No data available
Water Solubility:	No data available
Other Solubility:	DMSO (~5 mg/ml)
Boiling Point (°C):	No data available
Melting Point (°C):	No data available
Flash Point (°C):	No data available
Ignition Temperature (°C):	No data available
Density:	No data available

SECTION 10: STABILITY AND REACTIVITY

Property	Tofacitinib citrate
Chemical stability	Stable under recommended storage conditions
Conditions to avoid:	Protect from air and moisture
Materials to avoid:	Strong oxidizing agents
Hazardous decomposition products:	Carbon oxides, Nitrogen oxides (NOx)

SECTION 11: TOXICOLOGICAL INFORMATION

Tofacitinib citrate

Acute toxicity: No data available

Skin corrosion/irritation: No data available

Carcinogenicity:

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible, or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Serious eye damage/eye irritation: No data available

Respiratory or skin sensitization: No data available

Cell mutagenicity: No data available

Reproductive toxicity: No data available

Teratogenicity: no data available

Specific target organ toxicity – single exposure (GHS): no data available

Specific target organ toxicity – repeated exposure (GHS): no data available

Aspiration hazard: no data available

Potential Health Effects

Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.

Skin: May be harmful if absorbed through skin. May cause skin irritation.

Eyes: May cause eye irritation.

Ingestion: May be harmful if swallowed.

Signs and Symptoms of Exposure: To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Synergistic effects: no data available

Additional information: RTECS: not available

SECTION 12: ECOLOGICAL INFORMATION

Toxicity: No data available

Persistence and degradability: No data available

Bioaccumulative potential: No data available

Mobility in soil: No data available

Results of PBT and vPvB assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Other adverse effects: No data available

SECTION 13: DISPOSAL CONSIDERATION

Product: Observe all federal, state, and local environmental regulations.

Contaminated packaging: Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION

DOT (US): Not dangerous goods.

IMDG: Not dangerous goods.

IATA: Not dangerous goods.

SECTION 15: REGULATORY INFORMATION

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006.

OSHA Hazards: No known OSHA hazards

SARA 302 Components: SARA 302: No chemical in this material is subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components: SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title II, Section 313.

SARA 311/312 Hazards: No SARA Hazards

Massachusetts Right To Know Components: No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components: No components are subject to the Pennsylvania Right to Know Act.

New Jersey Right To Know Components: No components are subject to the New Jersey Right to Know Act.

SAFETY DATA SHEET
Cat# AUR11052, Tofacitinib citrate



Date: 9/01/2022

California Prop. 65 Components: This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

EU regulations:

Component	Risk Phrases	Safety Phrases
Tofacitinib citrate	--	--

SECTION 16: OTHER INFORMATION

DISCLAIMER:

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product regarding appropriate safety precautions. It does not represent any guarantee of the properties of the product. Aurora Medbiochem Co. shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.